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Abstract
● AIM: To evaluate the long-term effect and safety of focal 
laser photocoagulation treatment in eyes with polypoidal 
choroidal vasculopathy (PCV).
● METHODS: Medical records of 13 eyes of 13 patients 
with PCV were followed-up for more than 2y after focal 
laser photocoagulation treatment. The patients were 
diagnosed with PCV using indocyanine green angiography, 
and eyes with other comorbid ocular diseases were 
excluded. The measurement outcomes of the study were 
the post-treatment regression and recurrence of polyps, 
complications, and changes in visual acuities. Paired t-test 
was performed to compare visual outcome before and after 
the treatment.
● RESULTS: The mean age of the 13 patients was 
70.2±5.5y, and the follow-up period was 72.3±31.0 (range, 
25-118)mo. Three eyes had juxtafoveal polyps and 10 eyes 
had extrafoveal polyps. Of the 13 eyes, 9 eyes (69.2%) 
had regression of polyps 1.7±1.2 (range, 0.9-4)mo after 
focal laser photocoagulation. Five eyes (55.6%) showed 
recurrence of polyps during the follow-up periods, and the 
recurrence period was 12.8±18.9 (range, 1.9-48)mo. Mild 
subretinal hemorrhage occurred in two eyes (15.4%) 27 
and 72d after laser treatment, respectively. There were 
no statistically significant differences in visual acuities at 
baseline; 1, 2, 3y post-treatment (all P>0.05); and last 
follow-up (0.63±0.5, 0.73±0.70, 0.67±0.57, 0.75±0.7, and 
0.95±0.8 logMAR, respectively). 
● CONCLUSION: Focal laser photocoagulation is 
beneficial for early regression of polyps in eyes with PCV and 
does not result in significant submacular hemorrhage during 
the long-term follow-up. Furthermore, it can be primarily 
considered in eyes with PCV with extrafoveal or juxtafoveal 
polyps to regress risky polyps as well as to maintain visual 
acuity without serious hemorrhagic complications.
● KEYWORDS: long-term efficacy; polypoidal choroidal 
vasculopathy; focal laser photocoagulation
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INTRODUCTION
P olypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration 
characterized by a branching vascular network (BVN) and 
polypoidal dilatation of its termini, which is clinically shown 
as a reddish-orange polyp-like structure[1-2]. The prevalence 
of PCV varies from 20% to 60% in patients with neovascular 
age-related macular degeneration with ethnic predilection in 
East Asians[3].
Currently, PCV has various treatment options. Focal laser 
photocoagulation is the traditional treatment method where 
polyps identified by indocyanine green angiography (ICGA) 
are ablated. The early effect of focal laser photocoagulation 
was previously confirmed by optical coherence tomography 
angiography as well[4]. Verteporfin photodynamic therapy 
(PDT) and anti-vascular endothelial growth factor (VEGF) 
intravitreal injections emerged as effective treatment options 
for PCV. PDT monotherapy had some concerns over long-term 
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visual outcome[5]. LAPTOP study reported that ranibizumab 
group had better visual acuity than PDT group at 5-year 
follow-up[6]. EVEREST-II and PLANET studies concluded that 
both anti-VEGF monotherapy and combination therapy with 
PDT show favorable visual outcomes at 1y[7-8]. Nowadays, 
two treatments are commonly accepted as initial therapies 
for PCV. However, a long-term observational study revealed 
that about 30% of eyes with PCV develop massive subretinal 
hemorrhage that significantly deteriorates vision during 10y 
of follow-ups[9]. Another recent report showed that focal laser 
photocoagulation yielded a very low long-term incidence rate 
(0) of massive submacular hemorrhage compared to anti-
VEGF or PDT, which might have been related with the high 
rate of polyp regression post-laser treatment[10]. Previous 
reports showed cases of complete resolution of recalcitrant 
PCV after feeder vessel laser photocoagulation[11-12]. Thus, 
focal laser photocoagulation might have been undervalued and 
further assessment of its treatment efficacy may be needed.
In this study, we investigated the long-term effects and safety 
of focal laser photocoagulation treatment in eyes with PCV.
SUBJECTS AND METHODS
Ethical Approval  This study was approved by the 
Institutional Review Board of Seoul National University 
Bundang Hospital (IRB No.B-2003-601-111, Seongnam, 
Republic of Korea) and Yonsei University Severance Hospital 
(IRB No. 3-2019-0033, Seoul, Republic of Korea) adhered to 
the tenets of the Declaration of Helsinki. 
Subjects  We retrospectively reviewed the medical records 
of 13 eyes of 13 patients who were treated with focal 
photocoagulation for symptomatic PCV in Seoul National 
University Bundang Hospital and Gangnam Severance 
Hospital between May 2003 and February 2020. The 
patients were diagnosed with PCV by using the Japanese 
Study Group guidelines with ICGA[13]. We identified 
hyperfluorescent nodular polyps supplied by BVN via ICGA 
and located corresponding orange subretinal nodule on fundus 
photography. Patients with the presence of concomitant ocular 
diseases other than age related macular degeneration, such as 
glaucoma, diabetic retinopathy, retinal artery occlusion, and 
retinal vein occlusion were excluded from the study. Also, 
patients followed-up for less than 2y were not included.
Data Collection  The baseline demographics data of the 
patients included age, sex, initial visual acuity, slit-lamp 
biomicroscopy, fundus examination, optical coherence 
tomography (Spectralis OCT; Heidelberg Engineering Inc, 
Heidelberg, Germany), and ICGA findings.
We identified the locations of polyps by ICGA as follows: 
subfoveal, juxtafoveal, or extrafoveal. We performed ICGA 
before and after focal laser photocoagulation to check the 
regression and recurrence of polyps. The regression of the 
polyp was identified 1mo after the focal laser photocoagulation 
and was defined as reduction of more than half of the initial 
polyp size. The recurrence of polyps was identified 6mo after 
the treatment. Additional ICGA was performed when the 
recurrence of polyps was suspicious. The complication of 
subretinal hemorrhage was assessed by its size. When the size 
of subretinal hemorrhage was between 1 optic disc diameter 
(DD) and 4 DD, it was defined as a significant subretinal 
hemorrhage. When the size of hemorrhage was more than 4 DD, 
it was defined as a massive subretinal hemorrhage[9].
The focal laser photocoagulation of polyps was conducted 
by experienced retina specialists (Woo SJ, Park KH, and 
Lee CS). The spot size, exposure time, and power of laser 
was determined by the specialists performing the procedure. 
The laser photocoagulation was performed starting from 
low power and duration (200 mW, 50-100ms) which were 
gradually increased until the reddish polypoidal lesion became 
white. Also, anti-VEGF agents (bevacizumab, ranibizumab, 
or aflibercept) were injected intravitreally when needed at the 
discretion of the clinician. Most cases were included when 
persistent subretinal fluid or hemorrhage was present. We 
analyzed the number of intravitreal injections per year before 
and after the focal laser photocoagulation treatment. 
The measurement outcomes were the regression rate of polyps 
after focal laser photocoagulation, incidence of subretinal 
hemorrhage as complication, recurrence rate of polyp, changes 
in visual acuities, and the number of intravitreal injections per 
year during the follow-up period.
Statistical Analysis  Statistical analysis was performed 
using SPSS version 22.0 for Windows (SPSS, Inc, Chicago, 
IL, USA). Paired t-test was used to compare visual acuities 
before and after the focal laser treatment. A P value <0.05 
was considered statistically significant. The scatter plot was 
produced using GraphPad Prism version 8.00 for Windows 
(GraphPad Software, San Diego California USA, www.
graphpad.com).
RESULTS
The demographics, baseline characteristics, and clinical courses 
are depicted in Tables 1 and 2. Thirteen eyes of 13 patients 
were included in the study, and the mean age at the time of the 
laser treatment was 70.2±5.5y. Eight patients were male, and 
5 patients were female. The locations included 3 juxtafoveal 
polyps and 10 extrafoveal polyps, with no subfoveal polyps. 
The mean follow-up period was 72.3±31.0mo (range, 25-
118mo). Six eyes underwent intravitreal anti-VEGF injections 
in combination with focal laser photocoagulation.
Nine eyes (69.2%) showed regression of polyps after laser 
treatment. The mean regression period was 1.7±1.2mo (range, 
0.9-4mo). Of the 9 eyes with regressed polyps, 5 eyes (55.6%) 
recurred during the follow-up periods. The recurrence of 
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polyps occurred at 12.8±18.9mo (range, 1.9-48mo). Typical 
cases showing the regression or recurrence of polyps are 
depicted in Figures 1 to 3. Only two eyes (15.4%) showed the 
complication of newly appeared mild subretinal hemorrhage 
2.4 and 0.9mo after laser treatment, respectively.
The number of anti-VEGF injections per year was 2.1±2.4 
before the treatment, 2.3±2.2 at the first year, and 1.1±1.8 at 
the second year. The mean visual acuity at baseline, 3mo, 1, 
2, 3y, and final visit were 0.63±0.5, 0.57±0.58, 0.73±0.70, 
0.67±0.57, 0.75±0.7, and 0.95±0.8 logMAR, respectively. The 
comparison of pre-laser and final visual acuities are depicted in 
a scatter plot (Figure 4). There were no significant differences 
between visual acuities before and after the treatment (all 
P>0.05).
DISCUSSION
In this study, the effects and complications of focal laser 
photocoagulation were reviewed for a follow-up period of at least 
2y (the average follow-up period was 6y). Of 13 eyes, about 70% 
of eyes had regressed polyps immediately after laser treatment 
while 56% showed recurrence 23.1mo post-treatment. During 
the follow-up period, no massive submacular hemorrhages 
developed and the visual acuities remained the same. 
Table 1 Baseline characteristics and clinical courses of eyes with polypoidal choroidal vasculopathy




















1 72 F L Juxtafoveal No No Yes 1.6 No 0 84
2 66 M R Juxtafoveal No No Yes 1.1 No 0 82
3 73 F L Extrafoveal No No No N/A N/A N/A 115
4 67 M L Extrafoveal No No Yes 1.1 Yes 41.5 103
5 65 M L Extrafoveal No No No N/A N/A N/A 118
6 (Figure 3) 69 M L Extrafoveal No Yes Yes 1.2 Yes 14.0 63
7 77 F R Extrafoveal No No Yes 4 No 0 27
8 72 M L Extrafoveal No No Yes 1.3 No 0 25
9 59 M L Juxtafoveal No No Yes 0.9 Yes 10.0 39
10 76 F L Extrafoveal Yes Yes (significant) No N/A N/A N/A 61
11 70 F L Extrafoveal No Yes (significant) No N/A N/A N/A 98
12 79 M L Extrafoveal No No Yes 0.9 Yes 1.9 65
13 67 M L Extrafoveal No N/A Yes 3.4 Yes 48.0 60
Table 2 Demographics of patients and clinical courses
Parameters Mean±SD
Age (y) 70.2±5.5
Gender ratio (male%) 61.5%




Pre-laser subretinal hemorrhage 1 (7.7%)
Incidence of polyp regression 9/13 (69.2%)
Time to polyp regression (mo) 1.7±1.2
Polyp recurrence (%) 5/9 (55.6%)
Timing of polyp recurrence post-laser (mo) 12.8±18.9
BCVA, baseline (logMAR) 0.63±0.5 (range 0-1.40)
BCVA, final (logMAR) 0.95±0.8 (range 0.10-1.85)
Incidence of subretinal hemorrhage during follow-up periods 2/12 (16.7%)
Timing of subretinal hemorrhage post-laser (d) 49.5±31.8




VEGF: Vascular endothelial growth factor. 
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Several previous reports have investigated the regression rate 
of polyps after focal laser treatment. Lee et al[14] demonstrated 
that in 28 eyes, 18 eyes (64.3%) showed complete resolution 
of polyps during a 12-month follow-up period. Lafaut et al[15] 
reported that in 14 eyes, 10 eyes (71.4%) had regressed 
polyps 6mo after the treatment. Cho et al[10] reported a 
polyp regression rate of 100% (7 eyes of 7 eyes) after focal 
laser treatment. In our study, 9 of 13 eyes (69.2%) showed 
Figure 1 Images of a 63-year-old man with polypoidal choroidal vasculopathy in his right eye who was successfully treated with focal 
laser photocoagulation  Top row images show a round orange-colored subretinal nodule with exudates nearby (A), corresponding to the nodular 
choroidal vascular lesion shown on indocyanine green angiography (B) and dome-like elevation of retinal pigment epithelial detachment on 
optical coherence tomography (C). Images in the middle (D-F) and bottom (G-I) rows demonstrate successful regression of the polyp at 1 and 
12mo after the laser treatment, respectively.
Figure 2 Images of a 76-year-old man with polypoidal choroidal vasculopathy in his right eye who was successfully treated with focal 
laser photocoagulation  Images in the top row (A-C) show a round orange-colored subretinal nodule surrounded by a subretinal hemorrhage. 
Images in the middle (D-F) and bottom (G-I) rows demonstrate a decreased in polyp size 1 and 12mo after the laser treatment, respectively.
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resolution of polyps after a minimum follow-up period of 2y. 
These regression rates of polyps were relatively high compared 
to those after treatment with other modalities such as anti-
VEGF injections or PDT. In the PLANET and EVEREST-
II studies, the regression rates were 38.9% after intravitreal 
injection of aflibercept and 34.7% after intravitreal injection of 
ranibizumab, respectively[7-8].
Our study had two eyes with late post-treatment mild 
subretinal hemorrhage. All of them had failed closure of polyps 
after focal laser treatment. This result is compatible with those 
of a former study by Cho et al[10]. They demonstrated that 
the long-term massive submacular hemorrhage risk of PCV 
is higher in eyes with persistent polyps despite treatment, 
suggesting that treatment methods that can regress polyps are 
better for long-term visual preservation by avoiding massive 
submacular hemorrhages. The presumptive mechanism is that 
remaining active polyps may be subject to rupture, resulting 
in massive subretinal hemorrhage and irreversible damage to 
photoreceptors and retinal pigment epithelium.
There are concerns of polyp rupture after laser photocoagulation 
on polyps, but in this study, no massive subretinal hemorrhage 
was observed after laser treatment. Only mild subretinal 
hemorrhage not involving the fovea occurred in 2 of 13 eyes 
(15.4%). Taken together, the focal laser photocoagulation 
treatment can be safely performed in patients with PCV 
while substantially reducing the risk of future hemorrhages. 
In our previous study[10], additional anti-VEGF injections 
after PDT in eyes with PCV lowered the risk of massive 
submacular hemorrhage than PDT alone, which indicates 
that consistent anti-VEGF injections after focal laser 
treatment on PCV may reduce the long-term risk of polyp 
progression and massive submacular hemorrhage. This 
potential long-term effect of anti-VEGF agents needs to be 
confirmed by future studies.
Previous studies have reported a visual gain over 12mo after 
focal laser photocoagulations on eyes with PCV. Gemmy 
Cheung et al[16] reported that 28 of 33 eyes (84.9%) showed 
stable or improved vision for 1y. Lee et al[14] also reported that 
of 28 eyes, 75% showed stable or improved vision at 1y after 
laser treatment. Yuzawa et al[17] reported that about 90% of 
treated eyes showed visual gain or maintenance when polyps 
and network are treated by laser therapy concomitantly. In our 
study, although there was no significant visual gain after focal 
laser photocoagulation over 2 and 3y, the visual acuity was 
maintained during the long-term follow-up period of up to 10y 
post-laser treatment. 
Figure 3 Images of a 69-year-old man with polypoidal choroidal 
vasculopathy in his left eye with recurred polyp  Top row images 
were fundus photograph (A) and optical coherence tomography (B) 
at 6mo prior to a subretinal hemorrhage. Images in the second row 
(C, D) show the advent of subretinal hemorrhage as a complication 
of the polyp. The patient underwent focal laser treatment on the same 
day. Images in the third row (E, F) show a decrease in polyp size after 
1mo. Images in the bottom row (G-J) were taken 1y after the focal 
laser treatment and show the recurrence of polyp from the branching 
vascular network.
Figure 4 Scatter plot showing logMAR visual acuity (VA)  There 
were no statistical differences between baseline VA and the VA at each 
follow-up period (P>0.05).
Laser reatment for polypoidal choroidal vasculopathy
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The strength of our study is the long-term follow-up period: 
the average was 72.3mo with a minimum follow-up period 
of 25mo. To the best of our knowledge, this is the first study 
to report the long-term results of focal laser photocoagulation 
on eyes with PCV. Also, we investigated the regression and 
recurrence rates, unlike previous reports that focused mostly 
on visual gains only[14,16-17]. The limitations of our study are the 
retrospective nature of the study and the relatively small size of 
the cohort. Also, focal laser treatment can be limited because 
it can only be applied on eyes with extrafoveal or juxtafoveal 
polyps not involving the papillomacular bundle. Therefore, an 
appropriate treatment modality should be chosen in eyes with 
PCV considering the location of polyps. 
In conclusion, focal laser photocoagulation showed a high 
polyp regression rate without significant subretinal hemorrhage, 
while half of the eyes showed polyp recurrence more than 2y 
post-treatment. With a high rate of polyp regression and long-
term visual maintenance without significant hemorrhages, focal 
laser photocoagulation could be considered for the treatment of 
eyes with PCV that have juxtafoveal or extrafoveal polyps.
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